With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

A modified dosing regimen with Eli Lilly’s Alzheimer’s drug Kisunla (donanemab) has shown a reduction in amyloid-related ...

The cost of the drug, to be sold under the brand name Kisunla, will largely be covered by public health insurance from Nov.

People with schizophrenia often experience auditory hallucinations of voices that berate and bully them. New data suggests they may benefit from a type of behavioral therapy that uses digital avatars ...

The UK’s National Institute of Health and Care Excellence (NICE) said the drug provided only a small benefit to patients.

The Alzheimer's disease drug Kisunla will face major reimbursement challenges in the U.K. after the cost-effectiveness watchdog, NICE, said the drug isn't cost-effective.

Starting on a more gradual dosing schedule of Eli Lilly's Alzheimer's drug Kisunla cut the percentage of patients ...

LONDON — Britain's drug regulator approved the Alzheimer's drug Kisunla on Wednesday, but the government won't be paying for it after an independent watchdog agency said the treatment isn't ...

UK Regulator Approves Second Alzheimer's Drug in Months but Government Won't Pay for It LONDON (AP) — Britain's drug regulator approved the Alzheimer's drug Kisunla on Wednesday, but the ...

LONDON — Britain’s drug regulator approved the Alzheimer’s drug Kisunla on Wednesday, but the government won’t be paying for it after an independent watchdog agency said the treatment isn ...